



For Immediate Release

April 30, 2025

## **Sumitomo Chemical Announces Revisions to Its Financial Forecast for the Full Year Ending March 31, 2025**

Based on recent performance trends, Sumitomo Chemical Co., Ltd. (hereinafter, the "Company") has made revisions to its consolidated financial forecast for the full year ending March 31, 2025, previously announced on October 30, 2024, as detailed below.

### **Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2025**

(Millions of yen)

	Sales Revenue	Core Operating Income *	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	2,600,000	100,000	180,000	25,000	15.28
Revised forecast (B)	2,606,000	140,000	193,000	38,000	23.22
Variance in amount (B-A)	6,000	40,000	13,000	13,000	
Variance in percentage (%)	0.2%	40.0%	7.2%	52.0%	
Results for the full year ended March 31, 2024	2,446,893	(149,049)	(488,826)	(311,838)	(190.69)

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

### **Reasons for the Revision**

Regarding the consolidated financial results for FY2024, in Sumitomo Pharma, sales revenue for ORGOVYX® (therapeutic agent for advanced prostate cancer) increased in North America. In addition, in ICT & Mobility Solutions, there was an increase in shipments of display-related materials. The Company took into account uncertainty in the business environment and incorporated risks into its financial forecast, but it has made steady progress on company-wide efforts related to immediate-term, concentrated measures to improve business performance and business activities. Due to this, the Company expects that core operating income across all segments will exceed its previously released forecast. Operating income and net income attributable to owners of the parent are also expected to exceed the previous forecast due to the increase in core operating income.

### Cautionary Statement

Statements made in this document with respect to the Company's current plans, estimates, strategies and beliefs that are not historical facts are forward looking statements about the future performance of the Company. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; the Company's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

Information:

Financial Forecast by Segment for the Full Year Ending March 31, 2025

(Millions of yen)

		Fiscal 2024 Previous Forecast (A)	Fiscal 2024 Revised Forecast (B)	Variance in Amount (B-A)	Results for the Full Year ended March 31, 2024
Agro & Life Solutions	Sales revenue	550,000	540,000	(10,000)	515,617
	Core operating income	53,000	55,000	2,000	26,428
ICT & Mobility Solutions	Sales revenue	600,000	607,000	7,000	587,356
	Core operating income	65,000	71,000	6,000	50,021
Advanced Medical Solutions	Sales revenue	70,000	62,000	(8,000)	58,457
	Core operating income	3,000	4,000	1,000	6,062
Essential & Green Materials	Sales revenue	910,000	899,000	(11,000)	885,873
	Core operating income	(64,000)	(59,000)	5,000	(89,113)
Sumitomo Pharma	Sales revenue	380,000	398,000	18,000	313,832
	Core operating income	24,000	35,000	11,000	(126,449)
Others & Adjustments	Sales revenue	90,000	100,000	10,000	85,758
	Core operating income	19,000	34,000	15,000	(15,998)
Total	Sales revenue	2,600,000	2,606,000	6,000	2,446,893
	Core operating income	100,000	140,000	40,000	(149,049)

\*The Group changed its reportable segments from Q3 FY2024. The segment information for FY2023 has been reclassified to reflect the change in the reportable segments.